Neoplas Med, a Greifswald, Germany-based based medical technology company, received $18M in funding.
Niterra Ventures Company made the investment.
The company intends to use the funds to accelerate international expansion and technology platform development for treating infected and chronic wounds.
Led by CEO Ulrike Sailer, Neoplas Med is advancing the possibilities of argon cold plasma jet therapy in clinical use and is thus working to effectively and sustainably improve the quality of life of people with acute and chronic wounds. The company has created the argon cold plasma jet, kINPen® MED, a ‘plasma pen’ that directs a precise plasma jet onto wounds and significantly accelerates wound healing. Neoplas Med uses the inert gas argon for this rapid therapy, treating both infected and chronic wounds. With its ‘plasma pen,’ it is a manufacturer of cold plasma products in Europe that is European Medical Device Regulation (MDR) certified.
FinSMEs
25/11/2024